07.10.19
A randomized, double-blind, placebo controlled clinical study from Ohio State University Wexner Medical Center found that PrimaVie, a patented shilajit extract from Natreon, improved skin perfusion in healthy adult women. Results were published in the Journal of the American College of Nutrition.
PrimaVie is an organic humic substance containing urolithins, fulvic acid, and micro minerals. Natreon said it’s committed to continued scientific investment and research focused on the beauty-from-within and skin health categories. This marks the 10th clinical trial published by Natreon for its “biome optimized” shilajit extract.
The present study aimed to evaluate the effects of oral shilajit supplementation on skin gene expression profile and micro perfusion in healthy adult females. The study design comprised of six total study visits, including the baseline visit (V1), and a final 14-week visit (V6) following shilajit supplementation (125 or 250 mg bid).
A skin biopsy of the left inner upper arm of each subject was collected at visits two and six for gene expression profiling using Affymetrix Clariom D Assay. Skin perfusion was determined by MATLAB processing of dermascopic images. Transcriptome data were normalized and subjected to statistical analysis. The differentially regulated genes were subjected to Ingenuity Pathway Analysis (IPAV R). The expression of the differentially regulated genes identified by IPAV R were verified using real-time polymerase chain reaction (RT-PCR).
Supplementation with shilajit for 14 weeks was not associated with any reported adverse effect within this period. At the higher dose (250 mg bid), shilajit improved skin perfusion when compared to baseline or the placebo. Pathway analysis identified shilajit-inducible genes relevant to endothelial cell migration, growth of blood vessels, and ECM which were validated by quantitative RT-PCR analysis.
This work demonstrated that oral shilajit supplementation induced genes relevant to endothelial cell migration, collagens and other extra-cellular matrix (ECM) proteins and growth of blood vessels, and improved skin micro perfusion in healthy adult women.
“This study adds to the growing clinical evidence for all the anti-aging benefits of PrimaVie shilajit,” said Sanni Raju, CEO of Natreon. “Along with its earlier clinical studies, it’s proven that PrimaVie shows highly significant upregulations of genes coding collagens (especially, COL1A1) and ECM proteins in skeletal muscle, such effect being synergistic with exercise. It also has shown to improve testosterone levels, mitochondrial function (increased ATP levels), endothelial function and cardiovascular health in healthy subjects.”
PrimaVie is an organic humic substance containing urolithins, fulvic acid, and micro minerals. Natreon said it’s committed to continued scientific investment and research focused on the beauty-from-within and skin health categories. This marks the 10th clinical trial published by Natreon for its “biome optimized” shilajit extract.
The present study aimed to evaluate the effects of oral shilajit supplementation on skin gene expression profile and micro perfusion in healthy adult females. The study design comprised of six total study visits, including the baseline visit (V1), and a final 14-week visit (V6) following shilajit supplementation (125 or 250 mg bid).
A skin biopsy of the left inner upper arm of each subject was collected at visits two and six for gene expression profiling using Affymetrix Clariom D Assay. Skin perfusion was determined by MATLAB processing of dermascopic images. Transcriptome data were normalized and subjected to statistical analysis. The differentially regulated genes were subjected to Ingenuity Pathway Analysis (IPAV R). The expression of the differentially regulated genes identified by IPAV R were verified using real-time polymerase chain reaction (RT-PCR).
Supplementation with shilajit for 14 weeks was not associated with any reported adverse effect within this period. At the higher dose (250 mg bid), shilajit improved skin perfusion when compared to baseline or the placebo. Pathway analysis identified shilajit-inducible genes relevant to endothelial cell migration, growth of blood vessels, and ECM which were validated by quantitative RT-PCR analysis.
This work demonstrated that oral shilajit supplementation induced genes relevant to endothelial cell migration, collagens and other extra-cellular matrix (ECM) proteins and growth of blood vessels, and improved skin micro perfusion in healthy adult women.
“This study adds to the growing clinical evidence for all the anti-aging benefits of PrimaVie shilajit,” said Sanni Raju, CEO of Natreon. “Along with its earlier clinical studies, it’s proven that PrimaVie shows highly significant upregulations of genes coding collagens (especially, COL1A1) and ECM proteins in skeletal muscle, such effect being synergistic with exercise. It also has shown to improve testosterone levels, mitochondrial function (increased ATP levels), endothelial function and cardiovascular health in healthy subjects.”
